EMEA offers advice on producing vaccines
This article was originally published in The Gold Sheet
Executive Summary
The European Medicines Agency recently issued a guidance that gives pointers on the manufacture of live recombinant viral vector vaccines. The guideline notes that different approaches are being used to create these vaccines and the design of the viral vector upon which the vaccine is based "is central to product development, manufacture and safety and efficacy." The guideline notes that "the production of a live recombinant viral vectored vaccine is likely to follow that of other live viral vaccines in that in many cases there will be minimal downstream processing and the basic requirements for manufacture and control will be essentially similar … the method of production will involve the growth of the vaccine virus in the production cell line/substrate. Depending on the scale of production, it may be necessary to expand an ampoule of working seed before inoculation of the production cell culture." In addition, manufacturers should ensure that diluents, stabilizers or other types of excipients added during preparation of the final bulk vaccine not impair the safety and efficacy of the vaccine. The guidance updates a 2001 version that it said had provided "insufficient regulatory guidance" and had relied on outdated scientific principles. The deadline for comment is Nov. 30
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.